Double Chin Treatment (BELKYRA®)

Are you bothered by submental fullness (fat under your chin/ double chin)?

BELKYRA® (deoxycholic acid) is one of the first clinically evaluated and approved treatments for submental fullness. It is an injectable prescription medicine that offers a non-surgical alternative for stubborn fat under the chin that is not reduced with weight loss. It works by destroying the fat cells in this area and research has shown that this result is permanent.

BELKYRA® can provide a more contoured neck profile and jawline.

BELKYRA® is administered via a series of injections in the affected area. Typically, at least two treatments are required to see an improvement in submental fullness.

How many treatments will I need?

The total number of treatment sessions needed to achieve a satisfactory response depends upon the individual. Your doctor will determine how many treatments you need but most people require at least two treatments to achieve the desired result. These treatments are spaced 4-6 weeks apart for your comfort. No more than six treatments can be given.

Is there any downtime after treatment with BELKYRA®?

We aim to make your treatment as comfortable as possible. The BELKYRA® solution is mixed with local anaesthetic and we can use ice packs if required.

During the treatment, you may feel some mild pain and discomfort but patients report feeling more comfortable when the local anaesthetic starts working. Immediately after treatment you may notice the area under your chin is red and swollen – this is good! This means that the fat cells have burst and your body is trying to get rid of the cells. This swelling usually peaks at 24-48 hours but can last up to two weeks. This area may remain tender and lumpy for up to 6-8 weeks. We usually recommend patients receive their treatment toward the end of the week so they can have a few days at home if required – however this isn’t required by all of our patients.

Who is a suitable candidate for treatment with BELKYRA®?

If you are bothered by submental fullness or a pocket of fat under your chin that persists even with weight loss, then BELKYRA® will be an appropriate treatment for you. If you have saggy skin under the chin with very little fat, unfortunately BELKYRA® would not be appropriate.

Who cannot undergo treatment with BELKYRA®?

You should not receive treatment with BELKYRA® if you are pregnant or breast-feeding, as it is unknown if BELKYRA® is safe for pregnant or breast-feeding women.

If you have a liver condition such as chronic liver disease or hepatitis, HIV, or auto-immune condition, it is advised that you do not receive treatment with BELKYRA®.

To discuss if BELKYRA® is a suitable treatment for you, make your Initial Consultation Belkyra with either Dr Teresa Cattin or Leigh Cattin today

BELKYRA® injection is a prescription medicine containing 10 mg/mL deoxycholic acid. It is used for the improvement in the appearance of moderate to severe convexity or fullness associated with fat below the jaw in adults. 

Do not use in people: – allergic to this medicine, with infection at site of injection, pregnancy, and lactation. 

Possible side effects include headaches, difficulty swallowing, nausea, skin tightness, hypertension, injection site bruising/pain/swelling/numbness/redness/tingling/hardness/itching/discolouration/formation of small areas of hardness/warmth and injection site nerve injury.

BELKYRA® treatment is not funded on the New Zealand Pharmaceutical Schedule. You will need to pay for this medicine. Normal Doctor’s visit fees apply. BELKYRA® treatment should be administered only by trained medical professionals. Speak to your specialist about your own situation and about the benefits/risks of this procedure in appearance medicine. For further information, the Data Sheet and Consumer Medicines Information can be accessed at www.medsafe.govt.nz or ask your doctor. If you have any side effects or concerns speak to your doctor.

Note: Results from BELKYRA® treatment usually last up to 4 years. Allergan New Zealand Limited, Auckland.